Pyrazoline Scaffold: Hit Identification to Lead Synthesis and Biological Evaluation As Antidiabetic Agents

References

• Kabel AM . Zinc/alogliptin combination attenuates testicular toxicity induced by doxorubicin in rats: role of oxidative stress, apoptosis and TGF-β1/NF-κB signaling. Biomed. Pharmacother.97, 439–449 (2018).
   PubMed Web of Science ®Google Scholar
• Kabel AM , OmarMS , AlhadhramiA , AlharthiSS , AlrobaianMM. Linagliptin potentiates the effect of L-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced parkinsonism: role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Physiol. Behav.188, 108–118 (2018).
   PubMed Web of Science ®Google Scholar
• Macalino SJ , GosuV , HongS , ChoiS. Role of computer-aided drug design in modern drug discovery. Arch. Pharm. Res.38(9), 1686–1701 (2015).
   PubMed Web of Science ®Google Scholar
• Brough PA , AherneW , BarrilXet al. 4, 5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem.51(2), 196–218 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma S , PaliwalS , Singh , AkhterM. Molecular modelling of viral nucleocapsid protein zinc fingers modulators. IJBB53(1&2), 24–38 (2016).
   Google Scholar
• Makhouri FR , GhasemiJB. Combating diseases with computational strategies used for drug design and discovery. Curr. Top. Med. Chem.18(32), 2743–2773 (2018).
   PubMed Web of Science ®Google Scholar
• Sharma S , SrivastavaS , ShrivastavaAet al. Mining of potential dipeptidyl peptidase-IV inhibitors as anti-diabetic agents using integrated in silico approaches. J. Bimol. Struct. Dyn.38(18), 5349–5361 (2020).
   PubMed Web of Science ®Google Scholar
• Sharma S , SrivastavS , SinghGet al. In silico strategies for probing novel DPP-IV inhibitors as antidiabetic agents. J Biomol Struct Dyn.39(6), 2118–2132 (2021).
   PubMed Web of Science ®Google Scholar
• Kumari A , SinghRK. Medicinal chemistry of indole derivatives: current to future therapeutic prospective. Bioorg. Chem89, 103021 (2019).
   PubMed Web of Science ®Google Scholar
• Kumari A , SinghRK. Morpholine as ubiquitous pharmacophore in medicinal chemistry: deep insight into the structure–activity relationship (SAR). Bioorg. Chem96, 103578 (2020).
   PubMed Web of Science ®Google Scholar
• Sethi N , PrasadDN , SinghRK. An insight into the synthesis and structure–activity relationship (SAR) of 2, 4-thiazolidinedione (2, 4-TZD): a review. Mini-Reviews in Med. Chem.20(4), 308–323 (2020).
   PubMedGoogle Scholar
• Kato N , OkaM , MuraseTet al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl} amino)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg. Med. Chem.19, 7221–7227 (2011).
   PubMed Web of Science ®Google Scholar
• Bhat M , PoojaryB , KalalBSet al. Synthesis and evaluation of thiazolidinone-pyrazole conjugates as anticancer and antimicrobial agents. Future Med. Chem.10(9), 1017–1036 (2018).
   PubMed Web of Science ®Google Scholar
• Eid NM , GeorgeRF. Facile synthesis of some pyrazoline-based compounds with promising anti-inflammatory activity. Future Med. Chem.10(2), 183–199 (2018).
   PubMed Web of Science ®Google Scholar
• Bansal R , SinghR. Steroidal pyrazolines as a promising scaffold in drug discovery. Future Med. Chem.12(10), 949–959 (2020).
   PubMed Web of Science ®Google Scholar
• El-Sabbagh OI , BarakaM , IbrahimSet al. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur. J. Med. Chem.44(9), 3746–3753 (2009).
   PubMed Web of Science ®Google Scholar
• Bekhit AA , SaudiMN , HassanAMet al. Synthesis, molecular modeling and biological screening of some pyrazole derivatives as antileishmanial agents. Future Med. Chem.10(19), 2325–2344 (2018).
   PubMed Web of Science ®Google Scholar
• Chouiter MI , BoulebdH , PereiraDMet al. New chalcone-type compounds and 2-pyrazoline derivatives: synthesis and caspase-dependent anticancer activity. Future Med. Chem.12(6), 493–50 (2020).
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L . Dipeptidyl peptidase IV and its inhibitors: therapeutics for Type 2 diabetes and what else?J. Med. Chem.57(6), 2197–2212 (2014).
   PubMed Web of Science ®Google Scholar
• Meng W , BriganceRP , ChaoHJ. Discovery of 6-(aminomethyl)-5-(2, 4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J. Med. Chem.56(15), 5620–5628 (2010).
   Google Scholar
• Kim K , RheeS , KimHYet al. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. Eur. J. Pharmacol.518(1), 63–70 (2005).
   PubMed Web of Science ®Google Scholar
• Halimi S . DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of Type 2 diabetic patients?Diabetes Metab.34, S91–S95 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu T , ChenTC , TsaiTet al. (1,3-Diphenyl-1 H -Pyrazol-4-yl)-methylamine analogues as inhibitors of dipeptidyl peptidases. Chin. Chem. Soc.56(5), 1048–1055 (2009).
   Web of Science ®Google Scholar
• Gao Y , FengD , SheridanRPet al. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-IV inhibitors. Bioorg. Med. Chem. Lett.17(14), 3877–3879 (2007).
   PubMed Web of Science ®Google Scholar
• Xu J , OkHO , GonzalezEJet al. Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors. Bio. Med. Chem. Lett.14(18), 4759–4762 (2004).
   PubMed Web of Science ®Google Scholar
• Brockuner LL , HeJ , ColwellLFet al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bio. Med. Chem. Lett.14(18), 4763–4766 (2004).
   PubMed Web of Science ®Google Scholar
• Jun MA , ParkWS , KangSKet al. Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors. Eur. J. Med. Chem.43(9), 1889–1902 (2008).
   PubMed Web of Science ®Google Scholar
• Baell JB , HollowayGA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem.53(7), 2719–2740 (2010).
   PubMed Web of Science ®Google Scholar
• Brenk R , SchipaniA , JamesDet al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem. MedChem.3(3), 435–444 (2008).
   PubMed Web of Science ®Google Scholar
• Pourshojaei Y , AbiriA , EskandariK , HaghighijooZ , EdrakiN , AsadipourA. Phenoxyethyl piperidine/morpholine derivatives as PAS and CAS inhibitors of cholinesterases: insights for future drug design. Sci. Rep.9(1), 19855 (2019).
   PubMedGoogle Scholar
• Ertl P , SchuffenhauerA. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminfor.1, 8–17 (2009).
   PubMed Web of Science ®Google Scholar
• dos Santos JL , ChinCM. Pan-assay interference compounds (PAINS): warning signs in biochemical-pharmacological evaluations. Biochem. Pharmacol.4(2), e173–e174 (2015).
   Google Scholar
• Lagorce D , SperandioO , BaellJB , MitevaMA , VilloutreixBO. FAF-Drugs3: a web server for compound property calculation and chemical library design. Nucleic Acids Res.43, W200–W207 (2015).
   PubMed Web of Science ®Google Scholar
• Estrada-Valencia M , Herrera-ArozamenaC , PérezCet al. New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: multi-target-directed agents for Alzheimer′s disease endowed with neurogenic properties. J. Enzyme Inhib. Med. Chem.34(1), 712–727 (2019).
   PubMed Web of Science ®Google Scholar
• Ioakimidis L , ThoukydidisL , MirzaA , NaeemS , ReynissonJ. Benchmarking the reliability of QikProp. Correlation between experimental and predicted values. QSAR Comb. Sci.27(4), 445–456 (2008).
   Google Scholar
• Friesner RA , MurphyRB , RepaskyMPet al. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. J Med Chem.49(21), 6177–6196 (2006).
   PubMed Web of Science ®Google Scholar
• Sultan A , RazaRA , AbbasM , KhanMK , TahirNM , SaariN. Evaluation of silica-H2SO4 as an efficient heterogeneous catalyst for the synthesis of chalcones. Molecules18(8), 10081–10094 (2013).
   PubMed Web of Science ®Google Scholar
• Liu J , ChenggenM , XuemeiT , YuanC , ZichengL , WencaiH. Facile microwave assisted synthesis of substituted benzofuran derivatives. Res. Chem. Intermed.40, 2083–2090 (2014).
   Web of Science ®Google Scholar
• Zhao PL , WangF , ZhangMZ , LiuZM , HuangW , YangGF. Synthesis, fungicidal, and insecticidal activities of β-methoxyacrylate-containing N-acetyl pyrazoline derivatives. J. Agric. Food Chem.56(22), 10767–10773 (2008).
   PubMed Web of Science ®Google Scholar
• Langley AK , SuffoletaTJ , JenningsHR. Dipeptidyl peptidase IV inhibitors and the incretin system in Type 2 Diabetes Mellitus .Pharmacotherapy.27(8), 1163–1180 (2007).
   PubMed Web of Science ®Google Scholar
• Tanwar OP , TanwarL , ShaquiquzzamanMSet al. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors. Bioorg. Med. Chem. Lett.24(15), 3447–3451 (2014).
   PubMed Web of Science ®Google Scholar
• Choy M , LamS. Sitagliptin: a novel drug for the treatment of Type 2 diabetes. Cardiol. Rev.15, 264–271 (2007).
   PubMedGoogle Scholar